Is ZYME a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Ziihera moves into first-line gastric cancer, with revenue (ttm) at ~$37.1M. The bear case rests on zymeworks is not profitable and is not close to it on current product economics: the second quarter of 2026 produced a net loss of about $45.0 million on roughly $4.6 million of revenue, and operations run on a ~$322.5 million cash and securities balance plus lumpy partner payments rather than on product profits. Analysts covering it are spread from $31.00 to $60.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Zymeworks is not profitable and is not close to it on current product economics: the second quarter of 2026 produced a net loss of about $45.0 million on roughly $4.6 million of revenue, and operations run on a ~$322.5 million cash and securities balance plus lumpy partner payments rather than on product profits. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $31.00, +6.9% from the $29.01 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Ziihera moves into first-line gastric cancer. The August 2026 approval covers Ziihera with and without tislelizumab alongside chemotherapy in first-line HER2-positive gastroesophageal adenocarcinoma, based on the Phase 3 HERIZON-GEA-01 trial. The most optimistic analyst target on ZYME is $60.00, +106.8% from the $29.01 price. That figure is only reachable if this thesis works close to its best case.

Zymeworks is not profitable and is not close to it on current product economics: the second quarter of 2026 produced a net loss of about $45.0 million on roughly $4.6 million of revenue, and operations run on a ~$322.5 million cash and securities balance plus lumpy partner payments rather than on product profits. Nearly all of the value sits in assets the company does not control commercially, because Jazz and BeOne decide how hard Ziihera is promoted and where, or in wholly owned candidates still in Phase 1 with no efficacy proven at scale. Pipeline failure is a live possibility rather than a theoretical one, as the ZW171 discontinuation showed. The Theravance purchase adds cash flow but also adds closing risk, a $350 million non-recourse note secured on the YUPELRI profit share, and the job of running a commercial respiratory business Zymeworks has never operated. One approved drug carries the entire royalty line, so a competitive setback in HER2 gastroesophageal cancer, where Enhertu and trastuzumab-based regimens are entrenched, would fall directly on the only recurring revenue the company has. The most pessimistic published target is $31.00, +6.9% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Develops bispecific antibodies and antibody-drug conjugates, and earns royalties on zanidatamab, sold as Ziihera by Jazz Pharmaceuticals and BeOne.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Ziihera moves into first-line gastric cancer) stalling in the reported numbers rather than in the narrative, the risk above (zymeworks is not profitable and is not close to it on current product economics: the second quarter of 2026 produced a net loss of about $45.0 million on roughly $4.6 million of revenue, and operations run on a ~$322.5 million cash and securities balance plus lumpy partner payments rather than on product profits) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Zymeworks trades on the Nasdaq Global Select Market under the ticker ZYME, so any brokerage account that offers U.S. equities can hold it, including accounts that support fractional shares. Shares changed hands around ~$29.01 in late August 2026, giving a market value near ~$2.07 billion across roughly 71.0 million shares outstanding.

Zymeworks engineers bispecific antibodies and antibody-drug conjugates, mostly for cancer. Its lead molecule, zanidatamab, is licensed out and sold as Ziihera by Jazz Pharmaceuticals and by BeOne Medicines in Asia-Pacific markets, so Zymeworks earns royalties and milestone payments rather than selling anything itself. Everything else in the portfolio, including ZW191, ZW220 and ZW251, is a wholly owned candidate still in early clinical trials.

No. Zymeworks lost about $45.0 million in the second quarter of 2026 and about $89.2 million over the first half, and it funds itself from a ~$322.5 million cash and marketable securities balance plus partner payments rather than from product profits. Most of what the market is pricing rests on partnered assets that other companies commercialize and on clinical-stage candidates that have not yet proven themselves, so the shares behave like a claim on future events more than on current earnings.